Lucitanib Program Overview. August 2018
|
|
- Tyrone Fletcher
- 5 years ago
- Views:
Transcription
1 Lucitanib Program Overview August 2018
2 Lucitanib Background and Partnership Update Oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3) Partnered with Servier in 2013; Servier had rights to lucitanib worldwide, except for the U.S. and Japan, where Clovis holds rights Previously evaluated as monotherapy in breast and lung cancers in partnership Clovis has received notice from Servier that they will return their ex-u.s. rights (excluding China) for lucitanib later in 2018 Clovis to own global rights (excluding China) to lucitanib No payments from Clovis to Servier related to the return of these ex-us rights Composition of matter expires 2030 in the U.S. not including patent term extensions; EU patent protections will be similar 2
3 Recent Clinical Data Suggest a Compelling Alternate Hypothesis for Lucitanib Development Originally developed with the hypothesis of activity in FGFR driven tumors; monotherapy data in breast and lung cancer were insufficient to support continued development Recent data for a similar drug that inhibits FGF, VEGF and PDGF receptor TKwhen combined with a PD-1 inhibitor - provide rationale for development of lucitanib in combination with a PD-(L)1 inhibitor Clovis-sponsored combination studies now being planned Clovis also intends to initiate a study of lucitanib in combination with rucaparib, based on encouraging clinical data for vascular endothelial growth factor (VEGF) and PARP inhibitors in combination Each of these studies is expected to initiate before the end of Q
4 Lucitanib is a Potent Inhibitor of VEGFR1-3, PDGFR / and FGFR1-3 Lucitanib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors 1-3 (VEGFR1-3), platelet derived growth factor receptors (PDGFR) α/β and fibroblast growth factor receptors 1-3 (FGFR1-3) Kinome profiling 1 Kinase binding profiling 2 Kinase Kd (nm) FGFR1 21 FGFR2 41 FGFR3 51 VEGFR1 1 VEGFR2 1.1 VEGFR3 7.1 PDGFRα 0.43 PDGFRβ Source: 1 Clovis internal data; KINOMEscan kinase profiling of 456 kinases with 100 nm lucitanib performed at DiscoveRx; 2 Clovis internal data; Kinase binding performed at DiscoveRx.
5 Lucitanib Has a Similar Biochemical Kinase Inhibition Profile to Lenvatinib Lucitanib 1 Lenvatinib 1 < 10% 10-20% 20-30% 30-40% 5 Source: 1 Clovis internal data; Functional enzymatic inhibition of 455 kinases with 500 nm of the indicated compounds and 10mM ATP performed at Reaction Biology
6 Cellular Inhibition Profiles of Lucitanib and Lenvatinib Both lucitanib and lenvatinib are potent inhibitors of VEGFR, PDGFR and to a lesser extent, FGFR phosphorylation and RTK dependent cell proliferation Inhibition of RTK downstream signaling (IC 50, nm) 1 Cell line HUVEC H1703 HLE H1581 SNU-16 RT-112 Receptor VEGFR2 PDGFR PDGFR FGFR1 FGFR2 FGFR3 Lucitanib Lenvatinib Inhibition of cell proliferation (IC 50, nm) 1 Cell line HUVEC H1703 H1581 SNU-16 OPM-3 Receptor VEGFR2 PDGFR FGFR1 FGFR2 FGFR3 Lucitanib Lenvatinib ND 6 RTK=Receptor tyrosine kinase Source: 1 Servier and Clovis internal data
7 T u m o r v o lu m e m e a n S E M (m m 3 ) T u m o r v o lu m e (M e a n m m 3 S E M ) T u m o r v o lu m e (M e a n m m 3 S E M ) Lucitanib Anti-tumor Efficacy in Murine Xenograft Models Lucitanib monotherapy shows significant tumor growth inhibition in multiple preclinical models RT112/84 bladder RXF393 renal cell carcinoma MDA-MB-231 breast cancer D ays post-im plantation D a y s p o s t-tu m o r im p la n t D a y s p o s t-tu m o r im p la n t V e h ic le S unitinib 40m g /kg Q D Lucitanib 20m g /kg Q D Lenvatinib 20m g /kg Q D V e h ic le B e v a c iz u m a b u g /m ic e q 4 d x 8 S u n itin ib 4 0 m g /k g Q D L u c ita n ib 2 0 m g /k g Q D V e h ic le L u c ita n ib 1 5 m g /k g Q D S o ra fe n ib 6 0 m g /k g Q D 5 -F U 7 5 m g /k g IV q 9 d x 3 7 Source: 1 Servier and Clovis internal data
8 Targeting Angiogenesis and Immune Checkpoints Pathways May Have a Synergistic Effect on Antitumor Activity VEGF and other angiogenic factors promote the formation of new blood vessels (angiogenesis), which is often exploited by tumors to stimulate tumor growth and metastasis 1 Angiogenesis also has the ability to be immunosuppressive within the tumor microenvironment, dampening anti-tumor immune responses 1 Immune effects of angiogenesis include modulation of T-cell infiltration into the tumor, inhibition of dendritic cell maturation, modulation of cell adhesion molecules and immune cell populations Inhibition of angiogenesis by small molecule RTK inhibitors or monoclonal antibodies may reverse immunosupression 1 These data suggest the clinical activity of PD-(L)1 inhibitors may be enhanced through the inhibition of angiogenesis by lucitanib 8 Source: 1 Fukumara 2018 Nature Reviews in Clinical Oncology
9 Mechanisms of Angiogenesis Suppression of the Antitumor Immune Response Key: TAM Tumor associated macrophages MDSC Myeloid derived suppressor cells DC Dendritic cells CTL Cytotoxic T-lymphocytes T reg cell Regulatory T-cell 9 Source: Fukumara 2018 Nature Reviews in Clinical Oncology
10 Preclinical Data Support Angiogenesis + PD-(L)1 Inhibition Combination MMTV-PyMT (breast) and RT2-PNET (pancreatic) transgenic models DC101 (anti-vegfr2) or anti PD-L1 alone vs. combination of both agents Increased anti-tumor efficacy observed in both models; not in a third transgenic model (GBM) MMTV-PyMT RT2-PNET IgG control DC101 PD-L1 DC101 + PD-L1 10 GBM=Glioblastoma multiforme Source: Allen 2017 Science Translational Medicine
11 T u m o r v o lu m e (M e a n m m 3 S E M ) Lucitanib Plus Anti-PD-1 Combination More Active Than Monotherapy in Syngeneic Models H 2 2 H e p a to c e llu la r c a r c in o m a V e h ic le L u c ita n ib 1 0 m g /k g Q D L e n v a tin ib 1 0 m g /k g Q D A n ti-m P D -1 5 m g /k g B IW L u c ita n ib + A n ti- m P D - 1 L e n v a tin ib + A n ti- m P D D a y s p o s t-tu m o r im p la n t Increased anti-tumor efficacy of lucitanib + anti-pd-1 combination vs. monotherapy observed in syngeneic (immune competent) murine tumor model Similar results observed in EMT-6 (TNBC) and MC38 (CRC) models 11 mpd-1 = murine PD-1 Source: 1 Clovis internal data; Subcutaneous syngeneic model performed at Shanghai Medicilon, Inc., n=10. Line denotes dosing period for lucitanib, and arrows denote dosing for anti-pd-1.
12 Ongoing Angiogenesis/PD-(L)1 Inhibition Clinical Studies Multiple phase I-III studies are examining the combination of angiogenesis and PD-(L)1 inhibitors in different indications 1 Lenvatinib and pembrolizumab combination in metastatic renal cell carcinoma (mrcc) granted breakthrough designation (BTD) by FDA in January ,3 BTD based on 63% ORR (n=30) Objective responses seen in both the PD-L1 positive and PD-L1 negative tumors Lenvatinib and pembrolizumab combination in advanced and/or metastatic non-microsatellite instability high (MSI-H)/proficient mismatch repair (pmmr) endometrial carcinoma granted breakthrough designation (BTD) by FDA in July Source: 1 Fukumura 2018 Nature Reviews in Clinical Oncology; 2 lenvatinib-breakthrough-designation-for-rcc,
13 Lenvatinib and Pembrolizumab is Active in Advanced Endometrial Cancer Data presented at ASCO 2018 showed pembrolizumab/lenvatinib combination encouraging antitumor activity in patients with advanced endometrial cancer 53 patients with advanced, recurrent endometrial cancer 31/53 (59%) receiving 3rd or later line treatment 8% MSI high; 85% MSI not high; 8% MSI unknown ORR 40% (investigator); 47% (independent read) Median DOR not estimable Activity comparable in MSI high and MSI-non high Duration of treatment up to 120 weeks suggests durable activity 13 MSI=Microsatellite instability; ORR=Overall response rate, DOR=Duration of response, IRR=Independent Radiology Review Source: Makker ASCO 2018 Abs 5596
14 Lucitanib + Rucaparib Combination: Preclinical and Clinical Data Support Potential Activity of Angiogenesis and PARP Inhibition There is a link between PARP inhibition and suppression of angiogenesis - chronic hypoxia induces down-regulation of BRCA1 and RAD51 and decreases homologous recombination in cancer cells 1 The definition contextual synthetic lethality has been suggested for the therapeutic approach of inducing HRD by hypoxia with an anti-angiogenic in combination with PARP inhibitor Olaparib has been investigated in combination with the oral VEGFR inhibitor cediranib in recurrent ovarian cancer 2 PFS was 17.7 months for cediranib + olaparib arm versus 9.0 months for the single-agent olaparib arm (HR = 0.42, 95% CI = ; p = 0.005) Increased activity of cediranib + olaparib versus olaparib alone in the subgroup of patients with wild-type or unknown BRCA status, with an improvement in median PFS from 5.7 to 16.5 months (HR = 0.32, p = 0.008) and ORR from 32% to 76% (p = 0.006) 14 HRD=homologous recombination deficiency; PFS=progression free survival; HR=Hazard ratio; CI= Confidence interval Source: 1 Bindra 2004 Molecular and Cellular Biology, Bindra 2005 Cancer Research, Chan 2008 Cancer Research, Chan 2010 Cancer Research; 2 Liu Lancet Oncology 2014
15 T u m o r v o lu m e (M e a n m m 3 S E M ) P e rc e n t s u rv iv a l Lucitanib + Rucaparib Combination More Active Than Monotherapy in Preclinical Ovarian Tumor Model Combination of lucitanib plus rucaparib showed durable suppression of tumor growth in BRCA1 mut BrKras syngeneic murine model, while single agent lucitanib or rucaparib showed continued tumor growth BrKras BRCA1 mut syngeneic model Tumor Volume Survival D a y s p o s t tu m o r im p la n t D a y s p o s t-tu m o r im p la n t V e h ic le L u c ita n ib 5 m g /k g Q D R u c a p a rib 2 5 m g /k g B ID L u c ita n ib + R u c a p a rib Source: 1 Clovis internal data; Subcutaneous syngeneic model performed at Crown Bioscience, n=10
16 Lucitanib Preclinical Summary An oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3) Offers the potential benefit of targeting three relevant pro-angiogenic pathways, as well as simultaneously targeting proliferation and anti-vegfr therapy resistance driven by PDGF and FGF receptors Development opportunity for lucitanib in combination with a PARP inhibitor (rucaparib) or PD-(L)1 inhibitor in multiple tumor types 16
17 Lucitanib Clinical Development History Monotherapy development by Clovis and Servier focused on the hypothesis of activity in FGFR driven tumors (predominantly breast cancer) Completed Clovis sponsored studies: U.S. breast study: metastatic breast cancer in 178 patients 1 Lung cancer: metastatic lung cancer (SCLC/NSCLC) in VEGFR/PDGFR/FGFR genetic alterations in 17 patients 2 Completed Servier sponsored studies: FINESSE: metastatic breast cancer in 76 patients 3 INES: dose ranging study in solid tumors in combination with fulvestrant in 18 patients 4 FIM: Phase 1 study in solid tumors evaluating various dose schedules in ~134 patients 4 evaluated 5-30mg/day Recommended monotherapy dose 10 mg/day 4 Most patients (421/424 patients) in safety database treated at or above 10mg/day recommended dose Lucitanib monotherapy development in breast cancer discontinued in April 2017 Role of FGFR genomic amplifications as a driver in breast cancer questionable; clinical efficacy unlikely to be superior to standard-of-care 17 Source: 1 ClinicalTrials.gov NCT , 2 ClinicalTrials.gov NCT , 3 Study Report CL , 4 Lucitanib Investigator Brochure v7 Sept. 2016
18 Phase 1 Summary Phase 1 lucitanib monotherapy study enrolled 124/134 patients, evaluable for response across multiple tumor types Activity noted in thyroid patients (n=18) 2 Complete Responses 3 Partial Responses 12 Stable Disease 2 patients remain on drug > 6 years Initial recommended dose of 15 mg/day was reduced to 10 mg/day during the subsequent Phase 2 program 18 Source: Study report CL Final report
19 Adverse Event Profile of Lucitanib in Metastatic Breast Study Lucitanib TEAE 30% frequency, or grade 3 events 5% frequency Event Metastatic Breast Study (n=178) All grades Grade 3 Hypertension* 77% 48% Fatigue* 52% 6% Nausea 48% 3% Hypothyroidism* 45% <1% Headache 37% 3% Vomiting 33% 3% Decreased appetite 32% 1% Proteinuria 25% 6% Hyponatremia 10% 7% 19 TEAE=Treatment Emergent Adverse Events Source: CO CSR 14 April 2017 * combined terms
20 Lucitanib Clinical Development Plan: Combinations with PD-(L)1 and Rucaparib in Multiple Indications Initiate Phase 1b lucitanib combinations no later than Q Lucitanib and anti-pd-(l)1 Lucitanib and rucaparib (Clovis PARP inhibitor) Identify tumor types with the following criteria Scientific rationale for combination therapy Clear path to registration Clinical trials are feasible taking competition into account Several potential tumor types for lucitanib and anti-pd-(l)1 combination studies Strong clinical rationale to explore lucitanib and rucaparib in ovarian cancer 20
21 Lucitanib Summary Oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), plateletderived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3) Has the potential benefit of targeting three relevant pro-angiogenic pathways, as well as simultaneously targeting proliferation and anti- VEGFR therapy resistance driven by PDGF and FGF receptors Development opportunity for lucitanib in combination with a PARP inhibitor (rucaparib) and PD-(L)1 in multiple tumor types Clovis to own global rights (excluding China) to lucitanib in 2018 Composition of matter expires 2030 in the U.S. not including patent term extensions; EU patent protections will be similar 21
33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationRociletinib (CO-1686) April, 2015
Rociletinib (CO-1686) April, 2015 Lung adenocarcinoma is increasingly treated according to driver mutation Lung cancer incidence Worldwide: 1.2M cases per year UK: 43K cases per year Activating mutations
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationApproval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology
Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor
More informationFILED: NEW YORK COUNTY CLERK 03/29/ :57 PM INDEX NO /2016 NYSCEF DOC. NO. 59 RECEIVED NYSCEF: 03/29/2017 EXHIBIT J
EXHIBIT J ASCO Clinical Data Update May 31, 2015 The Langham Hotel, Chicago Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationImmunologic Effects of Clinical Stage FAK & PI3K-Delta/Gamma Inhibitors
1 Immunologic Effects of Clinical Stage FAK & PI3K-Delta/Gamma Inhibitors Jonathan Pachter, Ph.D - Chief Scientific Officer 3rd Annual Immuno-Oncology Congress, May 24, 2018 Disclosures 2 I am an employee
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationEisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co,. Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Execution of Comprehensive Strategic Collaboration for Eisai s In-house Discovered Anticancer Agent LENVIMA Eisai Conference for Media and
More informationORYX Translational Medicine. Dr. Dr. Sven Rohmann/ CBDO
ORYX Translational Medicine Dr. Dr. Sven Rohmann/ CBDO ORYX Overview Ø ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 1Q17 January February
BRAND NAME Rubraca GENERIC NAME rucaparib MANUFACTURER Clovis Oncology, Inc. DATE OF APPROVAL December 19, 2016 PRODUCT LAUNCH DATE December 19, 2016 REVIEW TYPE Review type 1 (RT1): New Drug Review Full
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationORYX Translational Medicine. Dr. Bernard Huber/ CEO
ORYX Translational Medicine Dr. Bernard Huber/ CEO ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationWHY TARGETTING SIGNALLING PATHWAYS?
WHY TARGETTING SIGNALLING PATHWAYS? Cancer cells are particularly sensitive to stress therefore sensitive to inhibition of their hyper activated signaling proteins the re instatement of lost tumor suppressors.
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationORYX Translational Medicine. Dr. Bernard Huber / CEO
ORYX Translational Medicine Dr. Bernard Huber / CEO BIO International Convention June 2016 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationR&D Presentation for Investors after FY2016
R&D Presentation for Investors after FY2016 Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationNew Developments in Ovarian Cancer
New Developments in Ovarian Cancer Daniela Matei, MD Professor Gynecology Oncology Northwestern University Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Outline Recent and ongoing
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationAddressing Key Mechanisms of Tumor Drug Resistance
Addressing Key Mechanisms of Tumor Drug Resistance April 2018 Kinase switch control inhibitors for tumortargeted and immune-targeted cancer therapies Disclaimer This presentation has been prepared by Deciphera
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationPrecision Therapeutics For Hard-To-Treat Cancers
Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationMedia Release. Basel, 18 February 2017
Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
More informationBackgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?
Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationEGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationAdvancing innovation towards breakthrough cancer therapies
Advancing innovation towards breakthrough cancer therapies LISTED EURONEXT Paris NASDAQ Copenhagen EPA: ONXEO 39th EORTC PAMM Winter meeting February 218 ASIDNA A FIRST-IN-CLASS COMPOUND TARGETING TUMOR
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationPatient-Centric Science-Based Performance-Driven
Patient-Centric Science-Based Performance-Driven Cowen & Co. 38 th Annual Health Care Conference Michael Pehl, President and Chief Executive Officer March 12, 2018 Forward-Looking Statements This presentation,
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationCalithera Biosciences. September 2018
Calithera Biosciences September 2018 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationThe PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction
The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More information